Stockscreener 앱 받기
44.50
0.20%
-0.09
시간 외 거래:
44.50
전일 마감가:
$44.59
열려 있는:
$44.8
하루 거래량:
1.66M
Relative Volume:
0.99
시가총액:
$5.83B
수익:
-
순이익/손실:
$-507.65M
주가수익비율:
-9.6739
EPS:
-4.6
순현금흐름:
$-616.24M
1주 성능:
-4.26%
1개월 성능:
-3.47%
6개월 성능:
+29.14%
1년 성능:
-49.36%
1일 변동 폭
$43.52
$44.92
1주일 범위
$42.55
$47.94
52주 변동 폭
$27.66
$93.77
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
44.50 | 5.84B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Vaxcyte, Inc. (PCVX) makes strides on pneumonia treatment, plots coverage extension - MSN
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Trading Systems Reacting to (PCVX) Volatility - news.stocktradersdaily.com
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com South Africa
Vaxcyte Finalizes Trial Design for VAX-31, Aiming to Set New Standard for Adult Pneumococcal Vaccines in Consultation with FDA - Quiver Quantitative
Vaxcyte Doses First Participants in the OPUS Phase 3, - GlobeNewswire
Jump Financial LLC Has $13.12 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Norges Bank Acquires Shares of 987,674 Vaxcyte, Inc. $PCVX - MarketBeat
Edgestream Partners L.P. Takes $1.61 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (BIT:1PCVX) Price Target Increased by 17.53% to 85.05 - Nasdaq
Vaxcyte (NASDAQ:PCVX) Trading Down 3.7%Here's Why - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Saturn V Capital Management LP - MarketBeat
American Century Companies Inc. Sells 236,002 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
JPMorgan Chase & Co. Decreases Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (NASDAQ:PCVX) Shares Gap DownHere's What Happened - MarketBeat
Can Vaxcyte Inc. (5VA) stock attract analyst upgrades2025 Technical Patterns & Growth Focused Stock Pick Reports - Newser
Quadrature Capital Ltd Takes $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Is Vaxcyte Inc. (5VA) stock a top hedge fund pickJuly 2025 Short Interest & Low Risk High Reward Ideas - Newser
Transcript : Vaxcyte, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02 - marketscreener.com
Transcript : Vaxcyte, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 02 - marketscreener.com
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Cipher Mining Lag - Barron's
XTX Topco Ltd Has $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
Franklin Resources Inc. Lowers Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
DNB Asset Management AS Acquires 6,924 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Entropy Technologies LP Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
Why Vaxcyte Inc. (5VA) stock remains stableJuly 2025 Closing Moves & Short-Term High Return Ideas - BỘ NỘI VỤ
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cash per share of Vaxcyte, Inc. – BX:PCVX - TradingView
Segall Bryant & Hamill LLC Grows Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Intech Investment Management LLC Sells 19,443 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
EBIT per share of Vaxcyte, Inc. – DUS:5VA - TradingView
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound - Yahoo Finance
How Vaxcyte Inc. stock reacts to Fed rate cutsWeekly Trade Report & Free Technical Pattern Based Buy Signals - newser.com
Is Vaxcyte Inc. stock vulnerable to regulatory risksEarnings Growth Report & Risk Managed Investment Entry Signals - newser.com
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
1.08%
0.91%
자본화:
|
볼륨(24시간):